| [1] |
李洪生, 吴湖炳, 王全师, 等. 18F-FDG PET-CT评价弥漫性大B细胞淋巴瘤化疗中期的治疗反应.中华核医学杂志, 2011, 31(3): 145-150. doi: 10.3760/cma.j.issn.0253-9780.2011.03.001
|
| [2] |
Meignan M, Itti E, Gallamini A, et al. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation-where do we stand?. LEUK lymphoma, 2009, 50 (11): 1753-1756. doi: 10.3109/10428190903308056
|
| [3] |
Imataki O, Tamai Y, Yokoe K, et al. The utility of FDG- PET for managing patients with malignant lymphoma: analysis of data from a single cancer center. Intern Med, 2009, 48(17): 1509-1513. doi: 10.2169/internalmedicine.48.1856
|
| [4] |
Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET-CT into the risk-adapted therapy of lymphoma. J Nucl Med, 2007, 48 suppl1: S19-27.
|
| [5] |
Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med, 2010, 51(12): 1857-1862. doi: 10.2967/jnumed.110.080556
|
| [6] |
阎骅, 沈志祥.淋巴瘤循证治疗解读.肿瘤, 2008, 28 (9): 733-735. doi: 10.3781/j.issn.1000-7431.2008.09.003
|
| [7] |
Petrausch U, Samaras P, Haile SR, et al. Risk-adapted FDG-PET-CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol, 2010, 21(8): 1694-1698. doi: 10.1093/annonc/mdq015
|
| [8] |
Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program, 2011, 116(21): 317-322.
|
| [9] |
李倩, 刘建军. 18F-FDG PET-CT评价淋巴瘤疗效及预后的价值.国际放射医学核医学杂志, 2011, 35(4): 220-222. doi: 10.3760/cma.j.issn.1673-4114.2011.04.006
|